Clinical profile, etiology, management and outcome of empyema thoracis associated with COVID-19 infection: A systematic review of published case reports

Abstract

Objective: To explore the clinical features, diagnosis, etiology, treatment, and outcomes of COVID-19 related empyema. Methods: Using PRISMA statement, a systematic search of relevant case reports published between December 2019 and April 2023 was performed through seven databases. The collected data included demographics, clinical manifestations, diagnostic findings, treatment, and outcomes. Results: Thirty-six case reports were identified with 43 cases of empyema. The included cases had a median age of 55 years (range: 12-78 years) and 79.1% (34/43) were males. The majority of cases presented during hospitalization for management of acute COVID-19 infection (29/43, 67.4%) and Charlson comorbidity index <3 (40/43, 93.0%). Pseudomonas aeruginosa was the most commonly isolated microorganism from the pleural fluid (9/43, 20.9%) and 16.3% of the cases (7/43) had polymicrobial infections. Chest drainage was performed in all cases while surgery was indicated in 24 cases (55.8%). The most common complication of COVID-19-related empyema was broncho-pleural fistula (2/43, 4.7%). The mortality rate was 23.3% (10/43). Sepsis and/or multi-organ failure were the most commonly reported causes of death. On univariate analysis, no statistically significant risk factor for mortality was identified. Conclusions: COVID-19-associated empyema has a variety of predisposing factors, time of presentation, clinical features, and causative organisms. Invasive or minimally invasive surgical procedures are performed more frequently than isolated chest drainage. Empyema in COVID-19 patients worsens their prognosis and can lead to serious complications.

Keywords

COVID-19 / SARS-CoV-2 / Empyema / Microbiology / Thoracic surgery

References

[1] WorldOMeter. Coronavirus toll update: Cases & deaths by country. [Online]. Available from:https://www.worldometers.info/coronavirus/ [Accessed on 1 May 2023].

[2] Borczuk AC, Yantiss RK. The pathogenesis of coronavirus-19 disease. J Biomed Sci 2022; 29(1):87. doi: 10.1186/s12929-022-00872-5.

[3] Jamil Z, Khalid S, Abbasi SM, Waheed Y, Ahmed J. Clinical outcomes of moderate to severe COVID-19 patients receiving invasive vs. noninvasive ventilation. Asian Pac J Trop Med 2021; 14(4):176-182.

[4] Saha BK, Chong WH, Austin A, Kathuria R, Datar P, Shkolnik B, et al. Pleural abnormalities in COVID-19: A narrative review. J Thorac Dis 2021; 13(7):4484-4499.

[5] Shen KR, Bribriesco A, Crabtree T, Denlinger C, Eby J, Eiken P, et al. The American Association for Thoracic Surgery consensus guidelines for the management of empyema. J Thorac Cardiovasc Surg 2017; 153(6):e129-e146.

[6] Taghavi M, Shokri A, Niloofar P, Poorbarat S, Mollazadeh S, Milani H. Chest CT features in COVID-19 patients: A systematic review and meta-analysis. J Acute Dis 2021; 10(5):179-189.

[7] Garvia V, Paul M. Empyema. Nih.gov. StatPearls Publishing; 2018. [Online]. Available from:https://www.ncbi.nlm.nih.gov/books/NBK459237/. [Accessed on 1 May 2023].

[8] Godfrey MS, Bramley KT, Detterbeck F. Medical and surgical management of empyema. Semin Respir Crit Care Med 2019; 40(3):361-374.

[9] Chong WH, Saha BK, Conuel E, Chopra A. The incidence of pleural effusion in COVID-19 pneumonia: State-of-the-art review. Heart Lung 2021; 50(4):481-490.

[10] McCauley L, Dean N. Pneumonia and empyema: Causal, casual or unknown. J Thorac Dis 2015; 7(6):992-998.

[11] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021; 372:n71. doi: 10.1136/bmj.n71.

[12] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40(5):373-383.

[13] Yarlagadda K, Mi K, Sendil S, Koons CL, Komanduri S, Cinicola JT. A 31-year-old man with COVID-19-associated empyema and lupus anticoagulant. Am J Case Rep 2020; 21:e926623. doi: 10.12659/AJCR.926623.

[14] Placik DA, Taylor WL, Wnuk NM. Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia. Radiol Case Rep 2020; 15(11):2378-2381.

[15] Glendening J, Koroscil M. A report of fungal empyema following recovery of severe SARS-CoV-2 infection. Chest 2020; 158(4):A566. doi: 10.1016/j.chest.2020.08.532.

[16] Leys L, Donaldson S, Rougui L, Poddar V. Severe acute respiratory syndrome coronavirus 2 isolation from pleural fluid with COVID-19 pneumonia and superimposed empyema. Chest 2020; 158(4):A574. doi: 10.1016/j.chest.2020.08.2124.

[17] Sharma A, Mehta N, Pirrotta S, Sheldon D, Juarez R. A tale of two species: First reported case of an empyema secondary to co-infection with SARS-CoV-2 and Candida albicans. Chest 2020; 158(4):A717. doi: 10.1016/j.chest.2020.08.673.

[18] Zavin A, Amith Shenoy M, Bender M. Spontaneous Enterococcus faecalis empyema in a patient with COVID-19. Chest 2020; 158(4):A774. doi: 10.1016/j.chest.2020.08.721.

[19] Tessitore A, Patella M, Giuliani M, Theologou T, Freguia S, Minerva EM, et al. Surgical treatment of pleural empyema in coronavirus disease 19 patients: The Southern Switzerland experience. Interact Cardiovasc Thorac Surg 2021; 32(3):367-370.

[20] Johan L, Dikken JL, Maat A, Wolf JL, Endeman H, Hoek RAS, et al. Organizing pneumonia and microvascular fibrosis as late sequelae after a COVID-19 infection: A case report. Surgeries 2021; 2(2):190-198. https://doi.org/10.3390/surgeries2020020.

[21] Testori A, Giudici VM, Alloisio M, Cioffi U. Case report: COVID-19 pneumonia following left pneumonectomy for lung cancer complicated by empyema and bronchopleural fistula. Front Surg 2021; 8:679757. doi: 10.3389/fsurg.2021.679757.

[22] Nakano T, Kawada M, Minami K, Kaneda H. Successful endobronchial occlusion in empyema with broncho-pleural fistula secondary to COVID-19 pneumonia: A case report and literature review. Respirol Case Rep 2021; 9(7):e00785. doi: 10.1002/rcr2.785.

[23] Gautam S, Pandit S, Bhadoria DP, Kumar R. Tubercular empyema thoracic: An acute presentation with COVID-19 co-infection. J Clin Diagnostic Res 2021; 15(6):6-9.

[24] Divisi D, Zaccagna G, Angeletti C, Cicerone E, De Vico A, Moretti R, et al. Pleural empyema associated with alveolar-pleural fistulas in severe acute respiratory syndrome coronavirus 2. Clin Case Rep 2021; 9(6):e04262. doi: 10.1002/ccr3.4262.

[25] Silalahi TDA, Suwita CS. Culture-negative pleural empyema after coronavirus disease-19 resolution-A case report. Respir Med Case Rep 2021; 34:101473. doi: 10.1016/j.rmcr.2021.101473.

[26] Ayad S, Gergis K, Elkattawy S, Mirza N, Abdelazeem B, Patel L, et al. Loculated empyema and SARS-CoV-2 infection: A report of two cases and review of the literature. Eur J Case Rep Intern Med 2021; 8(7):002706. doi: 10.12890/2021_002706.

[27] Mir M, Jones L, Levine S. Post-COVID-19-associated Aspergillus empyema and parenchymal abscess. Chest 2021; 160(4):A355. doi: 10.1016/j.chest.2021.07.357.

[28] Abbasi R, Javanmardi FS, Mokhtari A, Hosseinpour P, Shahriarirad R, Ebrahimi K. Management of pleural empyema in a 12-year-old obese patient with COVID-19: A pediatric case report. BMC Pediatr 2021; 21(1):531. doi: 10.1186/s12887-021-03007-1.

[29] Basnet A, Chaulagain S, Thapa A, Khadka M, Khadka M, Shrestha DB. Empyema thoracis in a patient admitted with COVID-19: A case report. JNMA J Nepal Med Assoc 2021; 59(244):1313-1315.

[30] Kalenchic TI, Kabak SL, Primak SV, Melnichenko YM, Kudelich OA. Bilateral parapneumonic pleural effusion with pneumothorax in a patient with covid 19 pneumonia: Case report. Radiol Case Rep 2022; 17(3):869-874.

[31] Qasem NM, Barakat M, Elamin N, Bashir M, Hassan IF. Candida albicans empyema in COVID-19 infected patient: The first reported case in Qatar. J Emerg Med Trauma Acute Care 2022: 10. doi: 10.5339/jemtac.2022.qhc.10.

[32] McCraw C, Forbush S, Trivedi K. Community-acquired, post-COVID-19, methicillin-resistant Staphylococcus aureus pneumonia and empyema. Cureus 2022; 14(2):e22121. doi: 10.7759/cureus.22121.

[33] Ahmed OF, Al-Neaimy S, Kakamad FH, Ali RK, Mikael TM, Hamasaeed AG, et al. COVID-19 associated with pulmonary mucormycosis; a case series. Ann Med Surg (Lond) 2022; 76:103434. doi: 10.1016/j.amsu.2022.103434.

[34] Crudeli C, Zilberman B, Williams J, Burg J, Shersher D. COVID-19's impact on lung tissue: A case report. Int J Surg Case Rep 2022; 92:106905. doi: 10.1016/j.ijscr.2022.106905.

[35] Bouassida I, Hadj Dahmane M, Zribi H, Abdelkbir A, Jaber C, Marghli A. Pyo pneumothorax revealing splenic tuberculosis abscess in a COVID-19 femmal: A case report. Int J Surg Case Rep 2022; 96:107312. doi: 10.1016/j.ijscr.2022.107312.

[36] Citak S, Vayvada M, Çardak ME, Geçmen G, Tasci E, Kirali K. Management of COVID-19-associated pleural empyema. Respir Case Rep 2022; 11(3):160-164.

[37] Pachauri A, Singh SN, Verma SK, Awasthi S. Thrombocytosis, haemorrhagic pleural effusion and fibro-infiltrative patches with cavitary lung lesions in a child with COVID-19 pneumonia. BMJ Case Rep 2022; 15(6):e249466. doi: 10.1136/bcr-2022-249466.

[38] Koda H, Sumiya R, Miyazaki H, Nagasaka S. Pyopneumothorax induced by rupturing of pneumatocele after COVID-19: A case report. Asian J Surg 2023; 46(2):1058-1059.

[39] Risal R, Jahir T, Islam R, Noel P, Subedi KR, Khan A, Kumari A, Schmidt M. A rare case of empyema complicated with bronchopleural fistula secondary to mucormycosis in a young immunocompromised diabetic patient with COVID-19. Cureus 2022; 14(7):e26635. doi: 10.7759/cureus.26635.

[40] Pourabdollah Toutkaboni M, Hakamifard A, Abtahian Z, Mirahmadian A, Rahdar M, Mokhber Dezfuli M, et al. Co-infection of Klebsiella pneumonia, Cytomegalovirus, Aspergillus and Zygomycete in a patient with SARS-CoV-2. Clin Case Rep 2022; 10(7):e6033. doi: 10.1002/ccr3.6033.

[41] Kumar R, Mishra N. Lung decortication for spontaneous hydropneumothorax in post COVID patients: A case series. Perioper Care Oper Room Manag 2022; 29:100279. doi: 10.1016/j.pcorm.2022.100279.

[42] Swaminathan N, Anderson K, Nosanchuk JD, Akiyama MJ. Candida glabrata empyema thoracis-A post-COVID-19 complication. J Fungi (Basel) 2022; 8(9):923. doi: 10.3390/jof8090923.

[43] Konagaya K, Yamamoto H, Nishida T, Morita T, Suda T, Isogai J, et al. Negative-pressure wound therapy to treat thoracic empyema with COVID-19-related persistent air leaks: A case report. Front Med (Lausanne) 2022; 9:970239. doi: 10.3389/fmed.2022.970239.

[44] Potla SC, Zia Z, Alkrekshi A, Kalayjian R, Kourouni I. Shewanella septic shock complicating COVID-19 survivorship following extracorporeal membrane oxygenation (ECMO) recovery. Chest 2022; 162(4):A465. doi: 10.1016/j.chest.2022.08.356.

[45] Goeryzen SM, Hall A, Boster J, Gadarowski M, Manninen E. Enterococcus empyema following extracoroporeal membrane oxygenation (ECMO) for COVID-19 ARDS. Chest 2022; 162(4):A463-A464. doi: 10.1016/j.chest.2022.08.355.

[46] Kubik H, Smyła W, Herba M, Białka S, Rydel M. Tracheo-esophageal fistula and pleural empyema in the course of SARS-CoV-2 infection-A case report. Clin Case Rep 2022; 10(10):e6400. doi: 10.1002/ccr3.6400.

[47] Kovalenko I, Golubykh K, Ali R, Mirza T, Malik M, Ramesh N. When nothing help: A rare case of COVID-19 empyema in a young healthy male. Chest 2022; 162(4):A1432. doi: 10.1016/j.chest.2022.08.1204.0.

[48] Gurung A, Poudel D, Gurung B, Rawal P, Chapagain S. Fatal pyopneumothorax in a COVID-19 patient. Cureus 2022; 14(11):e31866. doi: 10.7759/cureus.31866.

[49] Morris DE, Cleary DW, Clarke SC. Secondary bacterial infections associated with influenza pandemics. Front Microbiol 2017; 8:1041. doi:10.3389/fmicb.2017.01041.

[50] Chan KF, Ma TF, Sridhar S, Lam DC, Ip MS, Ho PL. Changes in etiology and clinical outcomes of pleural empyema during the COVID-19 pandemic. Microorganisms 2023; 11(2):303. doi: 10.3390/microorganisms11020303.

[51] Landstra CP, de Koning EJP. COVID-19 and diabetes: Understanding the interrelationship and risks for a severe course. Front Endocrinol (Lausanne) 2021; 12:649525. doi: 10.3389/fendo.2021.649525.

[52] Chong WH, Huggins JT, Chopra A. Characteristics of pleural effusion in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. Am J Med Sci 2021; 361(2):281-284.

[53] Wu HY, Chang PH, Chen KY, Lin IF, Hsih WH, Tsai WL, et al. Coronavirus disease 2019 (COVID-19) associated bacterial coinfection: Incidence, diagnosis and treatment. J Microbiol Immunol Infect 2022; 55(6 Pt 1):985-992.

[54] Guo L, Wei D, Zhang X, Wu Y, Li Q, Zhou M, et al. Clinical features predicting mortality risk in patients with viral pneumonia: The MuLBSTA score. Front Microbiol 2019; 10:2752. doi: 10.3389/fmicb.2019.02752.

[55] Torres A, Menéndez R, Wunderink RG. Bacterial pneumonia and lung abscess. In: Broaddus VC, Mason RJ. (eds.) Murray and Nadel's textbook of respiratory medicine. 6th ed. Philadelphia, PA: Elsevier Saunders; 2016, p. 557-582.e22. doi: 10.1016/B978-1-4557-3383-5.00033-6.

[56] Bergman R, Tjan DH, Schouten MA, Haas LE, van Zanten AR. Pleural Enterococcus faecalis empyema: An unusual case. Infection 2009; 37(1):56-59.

[57] Senger SS, Thompson GR 3rd, Samanta P, Ahrens J, Clancy CJ, Nguyen MH. Candida empyema thoracis at two academic medical centers: New insights into treatment and outcomes. Open Forum Infect Dis 2021; 8(4):ofaa656. doi: 10.1093/ofid/ofaa656.

[58] Talon A, Arif MZ, Mohamed H, Khokar A, Saeed AI. Bronchopleural fistula as a complication in a COVID-19 patient managed with endobronchial valves. J Investig Med High Impact Case Rep 2021; 9:23247096211013215. doi: 10.1177/23247096211013215.

[59] Molander V, Diakopoulou M, Orre L, Ferrara G. Chronic empyema: Importance of preventing complications in the management of pleural effusions. BMJ Case Rep 2013; 2013:bcr2013200454. doi: 10.1136/bcr-2013-200454.